Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Karen Allan
Observed name:
Allan, Karen
Institutions:
Beatson West of Scotland Cancer Centre,
University of Glasgow
Observed institutions:
University of Dundee,
Beatson West of Scotland Cancer Centre,
Cancer Research UK,
Hairmyres Hospital,
Ninewells Hospital,
University of Glasgow
show all 6
ORCID:
0000-0002-3887-0402
Observed ORCID:
0000-0002-3887-0402
OpenAlex ID:
A5000648403
Association analyses identify 31 new risk loci for colorectal cancer susceptibility
2019
·
Philip J. Law
, Maria Timofeeva
, et al.
·
Nature Communications
·
271
PDF
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial
2018
·
Timothy J Iveson
, Rachel S Kerr
, et al.
·
The Lancet Oncology
·
201
PDF
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial
2024
·
Nicoletta Colombo
, Elena Biagioli
, et al.
·
The Lancet Oncology
·
157
Demonstration of Blood Pressure-Independent Noninfarct Myocardial Fibrosis in Primary Aldosteronism: A Cardiac Magnetic Resonance Imaging Study
2012
·
E. Marie Freel
, Patrick B. Mark
, et al.
·
Circulation Cardiovascular Imaging
·
96
3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT
2019
·
Timothy Iveson
, Kathleen A Boyd
, et al.
·
Health Technology Assessment
·
40
PDF
Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trial
2025
·
Kenichi Harano
, Roldano Fossati
, et al.
·
Journal of Gynecologic Oncology
·
39
SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer
2018
·
José Robles-Zurita
, Kathleen A. Boyd
, et al.
·
British Journal of Cancer
·
25
PDF
Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy: Post Hoc Analysis of the SCOT Randomized Clinical Trial
2024
·
Mikail Gögenur
, Andreas Weinberger Rosen
, et al.
·
JAMA Surgery
·
22
Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial
2026
·
Timothy Iveson
, Mark P. Saunders
, et al.
·
Journal of Clinical Oncology
·
9
PDF
Three Versus Six Months of Adjuvant Doublet Chemotherapy for Patients With Colorectal Cancer: A Multi-Country Cost-Effectiveness and Budget Impact Analysis
2021
·
Catherine R. Hanna
, Jose A. Robles-Zurita
, et al.
·
Clinical Colorectal Cancer
·
7
PDF
Toxicity and quality of life data from SCOT: An international phase III randomized (1:1) noninferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy.
2015
·
Timothy Iveson
, Rachel Kerr
, et al.
·
Journal of Clinical Oncology
·
7
546 AtTEnd/ENGOT-EN7: phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma
2024
·
Nicoletta Colombo
, Kenichi Harano
, et al.
·
International Journal of Gynecological Cancer
·
2
523 Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of AtTEnd/ENGOT-EN7 trial
2024
·
Shin Nishio
, Beatriz Pardo
, et al.
·
International Journal of Gynecological Cancer
·
2
SCOT: Tumor sidedness and the influence of chemotherapy duration on DFS.
2018
·
Mark P. Saunders
, James Paul
, et al.
·
Journal of Clinical Oncology
·
1
Longitudinal Liquid Biopsy and Matched Radiomic Analysis Indicated Resistance Mechanisms of Patients with Biliary Tract Cancer Undergoing Systemic Treatment
2026
·
Giulia Tesini
, Jack Greaves
, et al.
·
Clinical Cancer Research
PDF
Matching-Adjusted Indirect Comparison Of Immunotherapy Versus Placebo In Combination With Carboplatin And Paclitaxel In Women With Advanced/Recurrent Endometrial Carcinoma
2025
·
Eliana Rulli
, Maria-Pilar Barretina-Ginesta
, et al.
·
International Journal of Gynecological Cancer
SCOT: Tumor Sidedness and the Influence of Adjuvant Chemotherapy Duration on Disease Free Survival (DFS)
2023
·
Mark P. Saunders
, Rohan Iype
, et al.
·
Clinical Colorectal Cancer
PDF
CeNtuRIOn: Rucaparib (R) with nivolumab (N) and ipilimumab (I) in patients (pts) with relapsed ovarian cancer (ROC)—Results of an initial safety cohort.
2022
·
Marcia Hall
, Karen Allan
, et al.
·
Journal of Clinical Oncology
An investigation of whether rucaparib is safe and more effective when combined with either one or two immunotherapy drugs (nivolumab and ipilimumab), when compared to rucaparib on its own
2018
·
Karen Allan
·
http://isrctn.com/
A Phase I/Ib Trial of the Oral Hedgehog inhibitor, LY2940680, in Combination with Weekly Paclitaxel in Patients with Platinum-Resistant, Recurrent Ovarian Cancer or Recurrent, Advanced, Solid Tumours.
2015
·
Karen Allan
·
http://isrctn.com/
Demonstration of blood pressure-independent diffuse cardiac fibrosis in Primary Aldosteronism- a cardiac MRI study
2012
·
Ellen Marie Freel
, Patrick Mark
, et al.
·
Endocrine Abstracts
Show more works
View as search
Works count:
22
Citation count:
879
H-index:
9
I10-index:
8
Year
Topic
Type